Comment on: benchmarking tocilizumab use for giant cell arteritis

HIGHLIGHTS

• who: Advance access publication et al. from the DepartmentUniversity Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK have published the article: Comment on: Benchmarking tocilizumab use for giant cell arteritis, in the Journal: Rheumatology Research, of 12/08/2022

SUMMARY

Published Shalini Janagan1, Catherine Guly2, Sarah Skeoch3, Joanna C. Robson Continuing TCZ beyond 12 months might prevent GCA relapse and associated morbidity, particularly in those with visual involvement, in whom relapsing disease can cause irreversible blindness and have a significant impact on function and health-related quality of life. The data underlying . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.